Anti-Human APP/Amyloid beta (CNTO 2125) (HY235206) is a research-grade recombinant antibody targeting AICD-57. Produced in mammalian cells with native-like glycosylation.
Highlights
●Research Grade — For PK/PD studies, assay development, and ADA research.
Protein A/G purified from cell culture supernatant.
Accession号
P05067
状态
Liquid
保存溶液
0.01M PBS pH 7.4
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名
CNTO-2125, CNTO2125, CNTO2125
背景
Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi).
1. Baumkötter, F. et al. (2014) The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 11159-72. PMID: 25122912
2. Satpute-Krishnan, P. et al. (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 16532-7. PMID: 17062754
